Claims · NAD+

Do NAD+ boosters slow ageing?

The claim

NAD+ levels fall with age; raising them with precursors such as nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), or with intravenous NAD+, restores cellular energy and repair pathways such as the sirtuins and so slows, or partly reverses, biological ageing.

The case for

  • “NAD levels are really important for keeping those sirtuin defenses at a youthful level. I take a precursor to NAD called NMN, and the body uses that to make the NAD molecule in one step.”

    David Sinclair, guest, Huberman Lab Essentials · 2025-10-30 · source

  • “We exist to improve healthspan by restoring and optimizing NAD+ levels, empowering people to live healthier and more vibrant lives as they age.”

    Niagen Bioscience, maker of Tru Niagen · 2026 · source

  • “The potent combination of NR and pterostilbene in Basis is designed to increase NAD+ levels and counter the decrease in the activity of sirtuins, which occurs with normal aging.”

    Elysium Health, maker of Basis (NR and pterostilbene) · 2026 · source

The case against

  • “I'm telling you that nicotinamide riboside is not a longevity drug”

    Charles Brenner, Beckman Research Institute of City of Hope; chief scientific advisor, Niagen Bioscience · 2025-09-18 · source

  • “Although our study shows a beneficial effect of NMN in skeletal muscle, it is premature to make any clinical recommendations based on the results from our study”

    Samuel Klein, director, Center for Human Nutrition, Washington University School of Medicine · 2021-04-22 · source

  • “Even thousands of anecdotes do not create evidence”

    David Seres, director of medical nutrition and professor of medicine, Columbia University Medical Center · 2025-09-18 · source

Quotes are short extracts, in the speakers' own words, about the claim or the evidence; each links to where it was said. Inclusion is not endorsement.

What the sources say

Evidence for this claim 5/10 · mixed or limited trials

NAD+ is a molecule cells use to turn food into energy and to run repair enzymes such as the sirtuins. A 2026 systematic review of 33 human intervention studies found that oral NMN and NR reliably raise NAD+ and related compounds in blood, but their effects on physical, metabolic and vascular measures were mixed and often absent, and it found no outcome trials of intravenous or intramuscular NAD+. The best-known NMN trial, in 25 women with prediabetes over 10 weeks, improved muscle insulin sensitivity but did not change blood glucose, blood pressure or blood lipids. A 2025 meta-analysis of randomised trials in adults over 60 found no effect of NMN or NR on muscle mass, grip strength or walking speed. No human trial has measured lifespan or the rate of ageing.

Scores slowing or reversing ageing with NMN, NR or IV NAD+: small, short trials of surrogate markers with mostly null outcomes; no trial of ageing itself, none at all of IV NAD+.

The record

Sources: hubermanlab.com, niagenbioscience.com, elysiumhealth.com, nationalgeographic.com, source.washu.edu, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov.

Compiled by the Alivewire editors from the sources above, ; evidence last checked . This page describes the published evidence on a claim; it makes no judgement about the people who make it. We rely on sources we consider reputable but do not independently verify the facts they report. Not medical advice.

If you are quoted here and believe we have misstated your position, or if the evidence has moved, please tell us; an editor checks every report and corrects the page when it holds. How claims pages work.

Explainer and coverage: NAD+